<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077532</url>
  </required_header>
  <id_info>
    <org_study_id>040083</org_study_id>
    <secondary_id>04-C-0083</secondary_id>
    <secondary_id>MDX-010-19</secondary_id>
    <secondary_id>NCI-6532</secondary_id>
    <secondary_id>CDR0000352187</secondary_id>
    <nct_id>NCT00077532</nct_id>
    <nct_alias>NCT00076167</nct_alias>
  </id_info>
  <brief_title>Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>A Study of Intra-Patient Escalating Doses of MDX-010 Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 in the Treatment of Patients With Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the&#xD;
      immune system and stop tumor cells from growing. Vaccines made from gp100 peptides may make&#xD;
      the body build an immune response to kill tumor cells. Combining the vaccines with Montanide&#xD;
      ISA-51 may cause a stronger immune response and kill more tumor cells. It is not yet known&#xD;
      whether monoclonal antibody therapy is more effective with or without vaccine therapy in&#xD;
      treating advanced melanoma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying monoclonal antibody therapy alone to see&#xD;
      how well it works compared to monoclonal antibody therapy, gp100 peptides, and Montanide&#xD;
      ISA-51 in treating patients with stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the clinical response in patients with stage IV melanoma treated with&#xD;
           escalating doses of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody&#xD;
           (MDX-010) with or without gp100 peptides emulsified in Montanide ISA-51.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety and toxicity profile of these regimens in these patients.&#xD;
&#xD;
        -  Determine the immunologic response in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the pharmacokinetics of these regimens in these patients.&#xD;
&#xD;
        -  Determine, in HLA-A*0201-positive patients, the differences in responses between&#xD;
           patients previously vaccinated with gp100 peptides and patients not previously&#xD;
           vaccinated.&#xD;
&#xD;
      OUTLINE: This is a 2-part, partially randomized study.&#xD;
&#xD;
        -  Part I (closed as of 3/7/2005):&#xD;
&#xD;
             -  HLA-A*0201-negative patients: Patients receive anti-cytotoxic&#xD;
                T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes&#xD;
                on day 1. Treatment repeats every 3 weeks for up to 6 doses (3 courses of 3&#xD;
                escalating doses) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  HLA-A*0201-positive patients: Patients are stratified according to prior exogenous&#xD;
                gp100 peptide immunization (yes vs no). Patients are randomized to 1 of 2 treatment&#xD;
                arms.&#xD;
&#xD;
                  -  Arm I: Patients receive MDX-010 in the same manner as the HLA-A*0201-negative&#xD;
                     patients.&#xD;
&#xD;
                  -  Arm II: Patients receive MDX-010 as in arm I. Patients also receive&#xD;
                     gp100:209-217 and gp100:280-288 peptides emulsified in Montanide ISA-51&#xD;
                     subcutaneously immediately after each MDX-010 infusion.&#xD;
&#xD;
        -  Part II:&#xD;
&#xD;
             -  HLA-A*0201-negative patients (closed as of 3/7/2005): Patients receive MDX-010 as&#xD;
                in part I. Treatment repeats every 3 weeks for up to 4 doses (2 courses of 2&#xD;
                escalating doses, beginning with a higher dose level than in part I) in the absence&#xD;
                of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  HLA-A*0201-positive patients: Patients are stratified and randomized as in part I.&#xD;
&#xD;
                  -  Arm I: Patients receive MDX-010 in the same manner as the HLA-A*0201-negative&#xD;
                     patients.&#xD;
&#xD;
                  -  Arm II: Patients receive MDX-010 as in arm I. Patients also receive&#xD;
                     gp100:209-217 and gp100:280-288 peptides emulsified in Montanide ISA-51&#xD;
                     subcutaneously immediately after each MDX-010 infusion.&#xD;
&#xD;
      In both parts, patients with stable disease or a complete response (CR) after completing all&#xD;
      courses of MDX-010 may receive 1 additional course of therapy in the absence of unacceptable&#xD;
      toxicity. Patients achieving a partial response may continue to recieve treatment with&#xD;
      MDX-010 at the same dose, in the absence of unacceptable toxicity, until CR or until tumor is&#xD;
      no longer shrinking.&#xD;
&#xD;
      Patients are followed at 3 weeks, every 3 months for 1 year, every 6 months for 2 years, and&#xD;
      then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35-179 patients (up to 35 for part I [closed as of 3/7/05] and&#xD;
      69-141 [23-47 per arm (arm I closed as of 3/7/05)] for part II) will be accrued for this&#xD;
      study within 3-4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response (partial and complete)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response activity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">179</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IV melanoma&#xD;
&#xD;
          -  Clinically evaluable or measurable disease&#xD;
&#xD;
          -  No mucosal or ocular melanoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Hematocrit ≥ 28%&#xD;
&#xD;
          -  WBC ≥ 2,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ ULN (&lt; 3 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C virus antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of any of the following:&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Regional enteritis&#xD;
&#xD;
               -  Connective tissue disorders (e.g., systemic lupus erythematosus)&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Autoimmune inflammatory eye disease&#xD;
&#xD;
               -  Sjögren's syndrome&#xD;
&#xD;
               -  Inflammatory neurologic disorder (e.g., multiple sclerosis)&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No active autoimmune disease that may cause life-threatening symptoms or severe&#xD;
             organ/tissue damage&#xD;
&#xD;
               -  Vitiligo, autoimmune thyroiditis, or skin rashes associated with prior therapy&#xD;
                  are allowed if patient has recovered to grade 1 or less toxicity&#xD;
&#xD;
          -  No systemic hypersensitivity to study agents&#xD;
&#xD;
               -  Prior local reaction (e.g., delayed hypersensitivity or glaucomatous reactions)&#xD;
                  to Montanide ISA-51 or gp100 injections allowed&#xD;
&#xD;
          -  No autoimmune disease requiring active therapy with any form of steroid or&#xD;
             immunosuppressant&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody&#xD;
&#xD;
          -  Prior therapy with gp100 peptides or any other immunotherapy allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas and recovered (toxicity no greater than&#xD;
             grade 1)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior steroids&#xD;
&#xD;
          -  No concurrent systemic, inhaled, optical, or topical corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior systemic therapy for melanoma and recovered (toxicity no&#xD;
             greater than grade 1)&#xD;
&#xD;
          -  No concurrent immunosuppressive agents (e.g., cyclosporine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

